The Claim
Six months of intravenous bimagrumab at 10 mg/kg in healthy adults aged 60–86 years has no significant effect on left ventricular mass index or left ventricular ejection fraction, despite increasing lean body mass by 5.5% and reducing fat mass by 14%.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In healthy adults aged 60 to 86, six months of intravenous bimagrumab at 10 mg/kg increases lean body mass and reduces fat mass without changing the size or pumping ability of the left ventricle of the heart.
See the scientific wording
Six months of intravenous bimagrumab at 10 mg/kg in healthy adults aged 60–86 years does not significantly alter left ventricular mass index or left ventricular ejection fraction, indicating no adverse effect on cardiac structure or function despite a 5.5% increase in lean body mass and 14% reduction in fat mass.
A drug blocks a signal that normally stops muscle growth and promotes fat storage, causing muscles to get bigger and fat to shrink. The heart does not grow larger or pump harder because the muscle gain is too small to demand more work from the heart, and the drug does not directly affect heart cells.
What the research says
1 studyThis study gave older adults a drug that made them gain muscle and lose fat, and then checked their hearts with a special scan. Their hearts didn't change in size or pumping strength, so the drug didn't hurt their hearts.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.